A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.

Autor: Nath, Karthik1 (AUTHOR), Shekarkhand, Tala2 (AUTHOR), Salcedo, Meghan2 (AUTHOR), Derkach, Andriy3 (AUTHOR), Rueda, Siobhan4 (AUTHOR), Chansakul, Aisara5 (AUTHOR), Hulcrantz, Malin2 (AUTHOR), Korde, Neha2 (AUTHOR), Shah, Urvi A.2 (AUTHOR), Tan, Carlyn2 (AUTHOR), Chung, David J.1,6 (AUTHOR), Lahoud, Oscar B.6 (AUTHOR), Hassoun, Hani2 (AUTHOR), Lesokhin, Alexander M.1,2 (AUTHOR), Landau, Heather J.6 (AUTHOR), Shah, Gunjan1,6 (AUTHOR), Scordo, Michael1,6 (AUTHOR), Giralt, Sergio A.1,6 (AUTHOR), Usmani, Saad Z.1,2 (AUTHOR), Roshal, Mikhail7 (AUTHOR)
Zdroj: Leukemia & Lymphoma. Dec2022, Vol. 63 Issue 14, p3488-3492. 5p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje